Medtronic plc (MDT) : The total money flow in Medtronic plc (MDT) was negative ($3.47 million), showing the domination of sellers in the Tuesday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $4.33 million. Transactions on upticks were comparatively lower at $0.86 million. The uptick to downtick ratio was 0.2. The total block trades on downticks were valued at $3.55 million. The money flow during block trades was negative ($3.55 million) when the stock traded with a gain of $11 cent. Medtronic plc (MDT) was $87.57, an increase of 0.13% over the previous days close.
Also, Equity Analysts at the Jefferies maintains the rating on Medtronic plc (NYSE:MDT). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $93 per share to $100 per share. The rating by the firm was issued on August 26, 2016.
Medtronic plc has lost 1.08% in the last five trading days and dropped 1.37% in the last 4 weeks. Medtronic plc is up 8.4% in the last 3-month period. Year-to-Date the stock performance stands at 14.05%.
Medtronic plc (NYSE:MDT): The stock opened at $87.35 on Tuesday but the bulls could not build on the opening and the stock topped out at $87.63 for the day. The stock traded down to $86.71 during the day, due to lack of any buying support eventually closed down at $86.85 with a loss of -0.70% for the day. The stock had closed at $87.46 on the previous day. The total traded volume was 3,088,519 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (EVP, President, MITG) of Medtronic Plc, Hanson Bryan C had sold 15,000 shares worth of $1,305,000 in a transaction dated July 26, 2016. In this transaction, 15,000 shares were sold at $87 per share.
Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.